Dr. Reddy’s Laboratories Transfers Unclaimed Dividends to IEPF

Dr Reddy’s Laboratories ( (RDY) ) has shared an announcement.

On May 28, 2025, Dr. Reddy’s Laboratories announced the publication of a notice regarding the transfer of unclaimed dividends and underlying equity shares to the Investor Education and Protection Fund (IEPF). This action is in compliance with Section 124(6) of the Companies Act, 2013. The move is part of the company’s efforts to adhere to regulatory requirements and ensure proper handling of unclaimed financial assets, impacting shareholders who have not claimed their dividends.

The most recent analyst rating on (RDY) stock is a Buy with a $17.40 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.

Spark’s Take on RDY Stock

According to Spark, TipRanks’ AI Analyst, RDY is a Outperform.

Dr Reddy’s Laboratories receives a solid overall score due to its strong financial performance, especially in revenue growth and balance sheet stability. Technical indicators show positive momentum, although the stock is below its long-term average. Valuation is reasonable, but dividend yield is low. The recent earnings call was positive, highlighting growth and strategic advancements despite some market challenges.

To see Spark’s full report on RDY stock, click here.

More about Dr Reddy’s Laboratories

Dr. Reddy’s Laboratories Limited is a pharmaceutical company based in Hyderabad, India. It is involved in the development and manufacturing of a wide range of pharmaceutical products, including generic medicines, active pharmaceutical ingredients, and biosimilars. The company operates globally and is listed on multiple stock exchanges, including the National Stock Exchange of India, BSE Limited, and the New York Stock Exchange.

Average Trading Volume: 2,076,095

Technical Sentiment Signal: Buy

Current Market Cap: $12.14B

See more insights into RDY stock on TipRanks’ Stock Analysis page.